T-cell receptor gene therapy for cancer
$2,022,756ZIAFY2021CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications, trials & patents
Paper 34116844Paper 33741731Paper 33558725Paper 31959727Paper 30646017Paper 29669936Paper 29528339Paper 29368612Paper 27037253Paper 26429982Paper 24329789Paper 24142051
Abstract
We have identified the genetic sequences of TCRs that target tumor antigens. We are testing genetically engineered T cells that express these TCRs for the treatment of patients with cancer. Our research is focused and on understanding response and resistance to these treatments with the goal to use this knowledge to develop more effective treatments. This work includes the discovery of technologies to identify biomarkers of response, enhance the efficacy of therapeutic T cells, and target new tumor antigens. Work on this project was completed in January 2021.
View original record on NIH RePORTER →